These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 1340161)
1. Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy. Zaia JA; Chatterjee S; Wong KK; Elkins D; Taylor NR; Rossi JJ Ann N Y Acad Sci; 1992 Oct; 660():95-106. PubMed ID: 1340161 [No Abstract] [Full Text] [Related]
2. Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents. Rossi JJ; Sarver N Adv Exp Med Biol; 1992; 312():95-109. PubMed ID: 1514448 [No Abstract] [Full Text] [Related]
3. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design. Tabler M; Homann M; Tzortzakaki S; Sczakiel G Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118 [TBL] [Abstract][Full Text] [Related]
4. Extension of helix II of an HIV-1-directed hammerhead ribozyme with long antisense flanks does not alter kinetic parameters in vitro but causes loss of the inhibitory potential in living cells. Homann M; Tabler M; Tzortzakaki S; Sczakiel G Nucleic Acids Res; 1994 Sep; 22(19):3951-7. PubMed ID: 7524030 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of infectious human immunodeficiency virus type 1 virions via lentiviral vector encoded short antisense RNAs. Gu S; Ji J; Kim JD; Yee JK; Rossi JJ Oligonucleotides; 2006; 16(4):287-95. PubMed ID: 17155905 [TBL] [Abstract][Full Text] [Related]
7. Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1. Homann M; Tzortzakaki S; Rittner K; Sczakiel G; Tabler M Nucleic Acids Res; 1993 Jun; 21(12):2809-14. PubMed ID: 8332489 [TBL] [Abstract][Full Text] [Related]
8. Length variation of helix III in a hammerhead ribozyme and its influence on cleavage activity. Hammann C; Martinez E; Moosbauer J; Hormes R; Tabler M Antisense Nucleic Acid Drug Dev; 1999 Feb; 9(1):25-31. PubMed ID: 10192286 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of gene expression with ribozymes. Marschall P; Thomson JB; Eckstein F Cell Mol Neurobiol; 1994 Oct; 14(5):523-38. PubMed ID: 7621511 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of SV40 gene expression by microinjected small antisense RNA and DNA molecules. Graessmann M; Michaels G; Berg B; Graessmann A Nucleic Acids Res; 1991 Jan; 19(1):53-8. PubMed ID: 1849259 [TBL] [Abstract][Full Text] [Related]
11. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents. Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650 [TBL] [Abstract][Full Text] [Related]
12. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition. Zhou C; Bahner I; Rossi JJ; Kohn DB Antisense Nucleic Acid Drug Dev; 1996; 6(1):17-24. PubMed ID: 8783792 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIV type 1 RNA dimerization by antisense DNA corresponding to the 17-nucleotide sequence downstream from the splice donor site of HIV type 1 RNA. Zhang S; Hara H; Kaji H; Kaji A AIDS Res Hum Retroviruses; 1997 Jul; 13(10):865-73. PubMed ID: 9197380 [TBL] [Abstract][Full Text] [Related]
14. HIV-1 TAR as anchoring site for optimized catalytic RNAs. Puerta-Fernandez E; Barroso-del Jesus A; Romero-López C; Berzal-Herranz A Biol Chem; 2003 Mar; 384(3):343-50. PubMed ID: 12715885 [TBL] [Abstract][Full Text] [Related]
15. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev. Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500 [TBL] [Abstract][Full Text] [Related]
16. Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16. Lu D; Chatterjee S; Brar D; Wong KK Cancer Gene Ther; 1994 Dec; 1(4):267-77. PubMed ID: 7627817 [TBL] [Abstract][Full Text] [Related]
17. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Yu M; Ojwang J; Yamada O; Hampel A; Rapapport J; Looney D; Wong-Staal F Proc Natl Acad Sci U S A; 1993 Jul; 90(13):6340-4. PubMed ID: 8327516 [TBL] [Abstract][Full Text] [Related]
18. Antiviral effects of herpes simplex virus specific anti-sense nucleic acids. Cantin EM; Podsakoff G; Willey DE; Openshaw H Adv Exp Med Biol; 1992; 312():139-49. PubMed ID: 1325101 [TBL] [Abstract][Full Text] [Related]
19. Design and anti-HIV-1 activity of ribozymes that cleave HIV-1 LTR. Koizumi M; Ozawa Y; Yagi R; Nishigaki T; Kaneko M; Oka S; Kimura S; Iwamoto A; Komatsu Y; Ohtsuka E Nucleic Acids Symp Ser; 1995; (34):125-6. PubMed ID: 8841584 [TBL] [Abstract][Full Text] [Related]
20. Effect of antisense ribozyme to pig alpha (1,3) galactosyl transferase gene on the expression of Gal alpha (1,3)Gal epitope. Hayashi S; Nagasaka T; Namii Y; Katayama A; Kozima T; Kobayashi T; Negita M; Yokoyama I; Saito I; Takagi H Transplant Proc; 1996 Apr; 28(2):628. PubMed ID: 8623312 [No Abstract] [Full Text] [Related] [Next] [New Search]